Sufficient Liquidity to Support Product Development Investment and M&A
First written in FY2020-Q1. 11 of 27 entries say "Restated". Latest entry: 2026-09-30.
Access moved to the "Worse" side of this theme in 2023, 3 years before the typical company in this theme (2026).
91 other companies' latest entry also says "Advanced".
- 2026-09-30AdvancedBusiness Alliances
「The purpose is to secure flexible and stable financing to meet the funding needs arising from the Group's business expansion.」
資金調達方針について、銀行とのコミットメントライン契約により、借入極度額30億円の機動的かつ安定的な調達手段が具体化した。 - FY2027-H1MitigatedAnnual report
「The balance of cash and cash equivalents at the end of the current interim consolidated accounting period was ¥6.827 billion. The company therefore expects to fund its needs with cash on hand and cash flows from operating activities.」
Cash and cash equivalents increased from ¥5.171 billion at the end of the previous fiscal year to ¥6.827 billion, while cash flows from operating activities also increased by ¥2.408 billion. The company maintained its policy of meeting its needs with cash on hand and operating cash flow while continuing to consider capital-market financing, bank borrowings and commitment lines. - 2026-06-12MitigatedEarnings
「Cash and deposits 5,407,627 7,055,391」
Cash and deposits increased from the end of the previous consolidated fiscal year, improving liquidity at the end of the first quarter compared with the recent decline in cash levels. - FY2026WorsenedAnnual report
「The Group's balance of cash and cash equivalents at the end of the current consolidated fiscal year was ¥5.171 billion. Although it expects to fund these needs with cash on hand and cash flows from operating activities, it will continue to consider raising funds in the capital markets or through bank borrowings in light of its medium- to long-term funding needs, with the aim of strengthening its financial base.」
Cash and cash equivalents declined from ¥10.560 billion to ¥5.171 billion, while cash flows from operating activities also declined by ¥3.935 billion. In addition to its policy of funding needs with cash on hand, the company continued to consider raising funds in the capital markets or through bank borrowings. - 2026-03-17WorsenedEarnings
「Cash flows from operating activities decreased by ¥3,935 million in the consolidated fiscal year under review, compared with an increase of ¥1,134 million in the previous consolidated fiscal year.」
Operating cash flow changed from an increase of ¥1,134 million to a decrease of ¥3,935 million, while cash and cash equivalents decreased from ¥10,559 million to ¥5,171 million. - FY2026-H1WorsenedAnnual report
「The balance of cash and cash equivalents at the end of the current interim consolidated accounting period was ¥6.063 billion. Although the company expects to fund its needs with cash on hand and cash flows from operating activities, it will continue to consider raising funds in the capital markets or through bank borrowings in light of its medium- to long-term funding needs, with the aim of strengthening its financial base.」
Cash and cash equivalents declined from ¥10.560 billion at the end of the previous consolidated fiscal year to ¥6.064 billion, while cash flows from operating activities also declined by ¥3.323 billion. The company continued to pursue a policy of funding its needs with cash on hand and other sources while continuing to consider capital-market financing and bank borrowings. - FY2025ReframedAnnual report
「As stated in Section 3, Capital Expenditures, 3. Plans for New Installations and Disposals of Facilities, product development investment for the fiscal year ending January 2026 is planned at ¥1.394 billion. The Group's balance of cash and cash equivalents at the end of the current consolidated fiscal year was ¥10.559 billion. Although it expects to fund these needs with cash on hand and cash flows from operating activities, it will continue to consider raising funds in the capital markets or through bank borrowings in light of its medium- to long-term funding needs, with the aim of strengthening its financial base.」
Although cash and cash equivalents increased from the end of the previous fiscal year, the company set product development investment at ¥1.394 billion based on its financial base after correcting prior-year figures, and expanded its policy to include continued consideration of capital-market financing and bank borrowings. - FY2025-H1WorsenedAnnual report
「The balance of cash and cash equivalents at the end of the current interim consolidated accounting period was ¥9.654 billion. Accordingly, the company has secured sufficient liquidity and believes that funding needs can be met with cash on hand and cash flows from operating activities.」
Cash and cash equivalents declined from ¥10.310 billion at the end of the previous consolidated fiscal year to ¥9.654 billion. The company continued to believe that it had secured sufficient liquidity to meet funding needs for product development investment, M&A and other purposes. - FY2025-Q1RestatedAnnual report
「The balance of cash and cash equivalents at the end of the current quarter was ¥10.336 billion. Accordingly, the company has secured sufficient liquidity and believes that funding needs can be met with cash on hand and cash flows from operating activities.」
Cash and cash equivalents amounted to ¥10.336 billion, reaffirming the company's view that funding needs for product development investment, M&A and other purposes could be met with cash on hand and operating cash flow. - FY2024WorsenedAnnual report
「As stated in Section 3, Capital Expenditures, 3. Plans for New Installations and Disposals of Facilities, product development investment for the fiscal year ending January 2025 is planned at ¥4.325 billion. The Group's balance of cash and cash equivalents at the end of the current consolidated fiscal year was ¥10.310 billion. It therefore expects to fund these needs with cash on hand and cash flows from operating activities and believes that it can secure sufficient liquidity.」
The product development investment plan increased from approximately ¥3.486 billion for the fiscal year ending January 2024 to ¥4.325 billion for the following fiscal year, while cash and cash equivalents declined to ¥10.310 billion. The company believes that it can meet these needs with cash on hand and operating cash flow. - FY2024-Q3WorsenedAnnual report
「The balance of cash and cash equivalents at the end of the third quarter of the current fiscal year was ¥10.706 billion. Accordingly, the company has secured sufficient liquidity and believes that funding needs can be met with cash on hand and cash flows from operating activities.」
Cash and cash equivalents declined from ¥11.584 billion at the end of the previous consolidated fiscal year to ¥10.706 billion. The company continued to believe that it had secured sufficient liquidity to meet funding needs for product development investment, M&A and other purposes. - FY2024-Q2WorsenedAnnual report
「The balance of cash and cash equivalents at the end of the second quarter of the current fiscal year was ¥10.941 billion. Accordingly, the company has secured sufficient liquidity and believes that funding needs can be met with cash on hand and cash flows from operating activities.」
Cash and cash equivalents declined from ¥11.584 billion at the end of the previous consolidated fiscal year to ¥10.941 billion. Meanwhile, the company maintained its view that it had secured sufficient liquidity to meet funding needs for product development investment, M&A and other purposes. - FY2024-Q1MitigatedAnnual report
「The balance of cash and cash equivalents at the end of the current quarter was ¥12.181 billion. Accordingly, the company has secured sufficient liquidity and believes that funding needs can be met with cash on hand and cash flows from operating activities.」
Cash and cash equivalents increased from ¥11.584 billion at the end of the previous fiscal year to ¥12.181 billion, and the company stated that it had secured sufficient liquidity to meet funding needs for product development investment, M&A and other purposes. - FY2023WorsenedAnnual report
「The Group's balance of cash and cash equivalents at the end of the current consolidated fiscal year was ¥11.584 billion. It therefore expects to fund these needs with cash on hand and cash flows from operating activities and believes that it can secure sufficient liquidity.」
Cash and cash equivalents declined from ¥15.092 billion at the end of the previous fiscal year to ¥11.584 billion. Meanwhile, the policy of funding product development investment of ¥2.874 billion for the fiscal year ending January 2024 with cash on hand and operating cash flow was maintained. - FY2023-Q3RestatedAnnual report
「The balance of cash and cash equivalents at the end of the third quarter of the current fiscal year was ¥12.413 billion. Accordingly, the company has secured sufficient liquidity and believes that funding needs can be met with cash on hand and cash flows from operating activities.」
Cash and cash equivalents declined from ¥13.308 billion at the end of the previous quarter to ¥12.413 billion, but the company continued to believe that it had secured sufficient liquidity to meet funding needs for product development investment, M&A and other purposes. - FY2023-Q2RestatedAnnual report
「The balance of cash and cash equivalents at the end of the second quarter of the current fiscal year was ¥13.308 billion. Accordingly, the company has secured sufficient liquidity and believes that funding needs can be met with cash on hand and cash flows from operating activities.」
Cash and cash equivalents declined to ¥13.308 billion, but the company continued to believe that it had secured sufficient liquidity to meet funding needs for product development investment, M&A and other purposes. - FY2023-Q1RestatedAnnual report
「As cash and cash equivalents stood at ¥14,719 million at the end of the quarter, we believe that sufficient liquidity has been secured and that funding needs can be met with funds on hand and cash flow from operating activities.」
Although the cash balance declined from the end of the previous fiscal year, the company continued to believe that product development investment, M&A and other needs could be covered by cash on hand and operating cash flow. - FY2022AdvancedAnnual report
「As stated in Section 3, Capital Expenditures, 3. Plans for New Installations and Disposals of Facilities, product development investment for the fiscal year ending January 2023 is planned at ¥2.392 billion.」
Under its policy of funding product development investment and M&A with cash on hand and operating cash flow, the company specified product development investment of ¥2.392 billion for the fiscal year ending January 2023. - FY2022-Q3RestatedAnnual report
「The balance of cash and cash equivalents at the end of the third quarter of the current fiscal year was ¥15.336 billion. Accordingly, the company has secured sufficient liquidity and believes that funding needs can be met with cash on hand and cash flows from operating activities.」
Cash and cash equivalents declined from ¥16.067 billion at the end of the previous quarter to ¥15.336 billion, but the company continued to believe that it had secured sufficient liquidity to meet funding needs for product development investment, M&A and other purposes. - FY2022-Q2RestatedAnnual report
「As cash and cash equivalents stood at ¥16,067 million at the end of the second-quarter consolidated accounting period, we believe that sufficient liquidity has been secured and that funding needs can be met with funds on hand and cash flow from operating activities.」
Although the cash balance declined, the company continued to believe that product development investment, M&A and other funding needs could be covered by cash on hand and operating cash flow. - FY2021AdvancedAnnual report
「As stated in Section 3, Capital Expenditures, 3. Plans for New Installations and Disposals of Facilities, product development investment for the fiscal year ending January 2022 is planned at ¥2.412 billion.」
Under its policy of funding product development investment, M&A and other needs with cash on hand and operating cash flow, the company specified product development investment of ¥2.412 billion for the fiscal year ending January 2022. - FY2021-Q3RestatedAnnual report
「The balance of cash and cash equivalents at the end of the third quarter of the current fiscal year was ¥17.495 billion. Accordingly, the company has secured sufficient liquidity and believes that funding needs can be met with cash on hand and cash flows from operating activities.」
Cash and cash equivalents declined from ¥18.078 billion at the end of the previous quarter to ¥17.495 billion, but the company maintained its view that it had secured sufficient liquidity to meet funding needs for product development investment, M&A and other purposes. - FY2021-Q2RestatedAnnual report
「The balance of cash and cash equivalents at the end of the second quarter of the current fiscal year was ¥18.078 billion. Accordingly, the company has secured sufficient liquidity and believes that funding needs can be met with cash on hand and cash flows from operating activities.」
Cash and cash equivalents declined to ¥18.078 billion, but the company continued to believe that it had secured sufficient liquidity to meet funding needs for product development investment, M&A and other purposes. - FY2021-Q1RestatedAnnual report
「The balance of cash and cash equivalents at the end of the current quarter was ¥19.160 billion. Accordingly, the company has secured sufficient liquidity and believes that funding needs can be met with cash on hand and cash flows from operating activities.」
Cash and cash equivalents declined to ¥19.160 billion, but the company continued to believe that it had secured sufficient liquidity to meet funding needs for product development investment, M&A and other purposes. - FY2020-Q3RestatedAnnual report
「The balance of cash and cash equivalents at the end of the third quarter of the current fiscal year was ¥19.682 billion. Accordingly, the company has secured sufficient liquidity and believes that funding needs can be met with cash on hand and cash flows from operating activities.」
Cash and cash equivalents declined from ¥20.514 billion at the end of the second quarter to ¥19.682 billion, but the company continued to believe that it had secured sufficient liquidity to meet funding needs for product development investment, M&A and other purposes. - FY2020-Q2RestatedAnnual report
「The balance of cash and cash equivalents at the end of the second quarter of the current fiscal year was ¥20.514 billion. Accordingly, the company has secured sufficient liquidity and believes that funding needs can be met with cash on hand and cash flows from operating activities.」
Cash and cash equivalents declined to ¥20.514 billion from the end of the previous consolidated fiscal year, but the company continued to believe that it had secured sufficient liquidity to meet funding needs for product development investment, M&A and other purposes with cash on hand and cash flows from operating activities. - FY2020-Q1First statedAnnual report
「The balance of cash and cash equivalents at the end of the first quarter of the current fiscal year was ¥22.632 billion. Accordingly, the company has secured sufficient liquidity and believes that funding needs can be met with cash on hand and cash flows from operating activities.」
It was first independently confirmed that the company could meet funding needs for product development investment, M&A and other investments with ¥22.632 billion in cash and cash equivalents and cash flows from operating activities.